I read about Ambilify but I am still not sure what it is used for? I noticed other people have it added to their antidepressant. Does it enhance and or add a better outcome?
Abilify is used in the treatment of bipolar disorder; major depressive disorder; agitated state; autism; depression (and more), and belongs to the drug class atypical antipsychotics.
It a very good medication, I have used it in the past, but bare in mind everyone reacts differently to medications.
more info; https://www.drugs.com/abilify.html
Abilify and its kind of a strange med, it sort of tunes up some Serotonin and Dopamine receptors and has a good chance of being a great med and a small chance of regret that you took it maybe even for 36-48 hours. I didn't like it, it caused severe agitation but way more often than not people benefit. Look into Rexulti and Latuda also
Hi, janie! Yes, Abilify is the drug that is commonly used to treat the conditions masso mentioned because it works on it's own but can also enhance other medications especially the antidepressants.
I've been taking Abilify (aripiprazole) for about 2yrs now and it's done wonders for me.
Best wishes, WCV
I think it is like an enhancer to the anti depressants and mood stabilizers. I took it for a year or two. Then it lost effectiveness and I was switched to Invega. Same kind of drug. In my opinion they were both bad news. Both seemed to lose effectiveness and I gained 100 pounds, developed type 2 diabetes and didn't even care. Even the box has warnings about potential blood sugar stuff. Anyway, water under the bridge. Stopped them. Weights gone too :) But the search for a balanced mind goes on.
- Abilify Information for Consumers
- Abilify Information for Healthcare Professionals (includes dosage details)
- Side Effects of Abilify (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 23 Jan 2015 • 6 answers
Posted 6 Feb 2015 • 2 answers
Posted 1 Apr 2017 • 1 answer
Posted 5 May 2017 • 6 answers
Posted 11 Sep 2017 • 1 answer